News | December 28, 2023
Elpiscience and Astellas collaborate for novel bispecific macrophage engager
Elpiscience will receive up to US $37 million, including the upfront payment and license option fees
Elpiscience will receive up to US $37 million, including the upfront payment and license option fees
Astellas has acquired abiraterone decanoate being developed by Propella to treat prostate cancer
Cresemba is the only azole antifungal therapy approved for pediatric patients as young as one affected by these serious, potentially life-threatening infections
XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy in nonmetastatic castration-sensitive prostate cancer
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
Cullgen will have the option during the initial stages of clinical development to participate equally in the costs, profits and losses
Ministry of Health, Labour and Welfare to evaluate zolbetuximab as treatment option for patients with advanced gastric and gastroesophageal cancers
VEOZAH is first-in-class treatment option to reduce the frequency and severity of moderate to severe VMS due to menopause
CiRA, Kyoto University and Astellas - Second Phase Joint Research Agreement Signed for Medical Applications of iPS Cells
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)